Expert Available: Why 2026 Will Reshape Access to GLP-1 Weight Loss Drugs

Newswise — A major shift is coming to the GLP-1 weight loss drug market in 2026 — one that could dramatically change who can access these medications, how they’re taken, and how much they cost.

After years defined by shortages, high prices, and weekly injections, GLP-1 drugs like Wegovy and Zepbound are entering a new era. Oral weight loss pills are arriving, competition is increasing, and cash-pay programs and retailer partnerships are reshaping access for people whose insurance doesn’t cover obesity treatment.

What’s changing:

• First GLP-1 weight loss pill approved: Novo Nordisk’s oral Wegovy is expected to be widely available, with another pill from Eli Lilly likely later this year — offering a needle-free option many patients prefer.
• Lower prices, more competition: Starting doses of GLP-1 pills are expected to cost as little as $149 a month for cash-paying patients, compared with $349 or more for injections.
• More powerful injections on the horizon: Lilly’s experimental drug retatrutide produced nearly 29% average weight loss in trials — the highest seen yet — but with higher dropout rates due to side effects.

George Washington University experts are available to discuss these changes. If you would like to schedule an interview, please contact Katelyn Deckelbaum, katelyn.deckelbaum@gwu.edu

Leighton Ku, a professor of health policy and management and Director of the Center for Health Policy Research at the GW Milken Institute School of Public Health, is a health policy researcher and public policy analyst. He is an expert in national and state health reforms.

Richard Ricciardi is associate dean for Clinical Practice and Community Engagement in the GW School of Nursing and the executive director for the Center for Health Policy and Media Engagement.

Tony Yang, is a professor in health policy at the George Washington University School of Nursing with a joint appointment at the Milken Institute School of Public Health in the Department of Health Policy and Management.

William Dietz is the director of the Sumner M. Redstone Global Center for Prevention and Wellness at the GW Milken Institute School of Public Health. 

-GW-